Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing

NCT07290816 | Not Yet Recruiting

• 1 other identifier: 2023YS-077 Amendment 1
• Study Type: interventional
• Target: 270
• Locations: 1 country
• Sites: 1

Brief Summary

To clarify whether non-invasive neuromodulation for assisted bowel preparation can improve the quality of bowel preparation, to explore the possible mechanisms by which TEA improves the quality of bowel preparation, and to assess its safety, as well as subjects' tolerance, compliance and satisfaction.

Conditions

Intestinal Polyps

Keywords

Bowel Preparation; Noninvasive electrical neuromodulation

Outcome Measures

Primary Outcomes (1)

• Bowel Preparedness Score

  Using the Boston Bowel Preparation Scale(BBPS)

  Day 2

Secondary Outcomes (7)

• Polyp detection rate

  Day 2

• Adenoma detection rate

  Day 2

• Adverse reactions

  Baseline and Day 2

• Complete Blood Count

  Baseline and Day 2

• C-Reactive Protein

  Baseline and Day 2

Study Arms (3)

Trial Group 1

EXPERIMENTAL

Bowel pacing (specific location and parameters) and ST36 acupoint stimulation (specific location and intensity) were used the day before the examination; 2L of PEG was taken the night before the examination and on the day of the examination, and 30 ml of simethicone was taken orally immediately after all of the 4L of PEG had been taken. Colonoscopy was completed within 2-6 hours after bowel preparation was completed.

Other: Intestinal pacing + ST36 acupoint stimulation

Trial Group 2

EXPERIMENTAL

Sham acupoint bowel pacing and sham ST36 acupoint stimulation were used the day before the examination (electrode pads were offset and current switch was not turned on; 2L of PEG was taken the night before and on the day of the examination, respectively, and 30 ml of simethicone was taken orally immediately after all of the 4L of PEG had been taken. Colonoscopy was completed within 2-6 hours after bowel preparation was completed.

Other: Sham acupoint intestinal pacing + sham ST36 acupoint stimulation

Control Group

NO INTERVENTION

Only conventional treatment was used, with 2 portions of 2000 ml PEG taken with fasting starting at 19:00 pm the night before the examination and required to be taken within 2 hours. On the day of the examination, 2 doses of 2000 ml of PEG were taken orally starting 3-5 hours before the colonoscopy procedure, which was required to be completed within 2 hours, and 30 ml of simethicone was taken orally as soon as the subject had finished taking the laxative, and all bowel preparations had to be completed more than 2 hours and less than 6 hours before the colonoscopy procedure, and if the time limit was exceeded the subject was excluded from the study.

Interventions

Intestinal pacing + ST36 acupoint stimulation OTHER

The day before the examination began a real stimulation treatment, namely, intestinal pacing (① location: positive pole placed on the navel (the line between the raphe and navel) 1 to 2 cm, the negative pole in the raphe and the navel line at the midpoint of the right 4 to 10 cm; ② parameters: the intestinal frequency: 2.4-3.7 cpm, the first time the frequency of use of 3.0 cpm, treatment of the base wave intensity of 0-15 gears, the first time to use the intestinal treatment intensity of 10 gears) , acupoint stimulation (① location: treatment sheet attached to both legs ST36 acupoints, i.e., four transverse fingers below the eye of the outer knee, 4 transverse fingers next to the tibia; ② parameters: the first use of acupoint intensity 30%, to the patient's self-conscious stimulation points have a slight pinprick sensation, lifting sensation, warm sensation is appropriate).

Trial Group 1

Sham acupoint intestinal pacing + sham ST36 acupoint stimulation OTHER

A sham stimulation treatment was started one day before the examination, i.e., intestinal pacing treatment with the electrode pads offset to the lumbar side to stimulate the sham acupoints, and acupoint stimulation with the treatment pads applied to the ST36 acupoints but without turning on the current switch.

Trial Group 2

Eligibility Criteria

• Age: 18 Years - 78 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• to 78 years of age, male or female;
• Intended to undergo diagnostic, screening, or surveillance colonoscopy;
• Signed written informed consent.

You may not qualify if:

• Severe cardiac, cerebral, pulmonary, or renal complications or a history of acute cardiac infarction within six months;
• High risk factors for bowel preparation such as history of colon surgery, BMI ≥ 28, inflammatory bowel disease, constipation (less than 3 bowel movements in the last week, and with straining to defecate, with hard stools and small amount of stools) or bowel obstruction;
• High suspicion of colorectal cancer by auxiliary examination or early warning signs and symptoms of colorectal cancer: blood in stool, black stool, unexplained anemia, significant weight loss, abdominal mass and positive rectal fingerprinting;
• The presence of surgical incisions or scars in the area where the electrostimulation treatment tablets are pasted, or near the ST36 acupoints on both legs;
• Are participating in other clinical observation trials or have participated in other clinical trials within 30 days.

Sponsors & Collaborators

• Shanghai East Hospital: lead

Study Sites (1)

Shanghai East Hospital

Shanghai, China

Location

MeSH Terms

Conditions

Intestinal Polyps

Condition Hierarchy (Ancestors)

Polyps; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Lan Zhong

CONTACT

+86 13162099450; lanzhong@tongji.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 29, 2025
• First Posted: December 18, 2025
• Study Start: December 31, 2025
• Primary Completion (Estimated): March 21, 2027
• Study Completion (Estimated): March 21, 2028
• Last Updated: December 18, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)